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OBJECTIVE—Matricellular Secreted Protein, Acidic and Rich
in Cysteine (SPARC), originally discovered in bone as osteonec-
tin, is a mediator of collagen deposition and promotes ﬁbrosis.
Adipose tissue collagen has recently been found to be linked with
metabolic dysregulation. Therefore, we tested the hypothesis
that SPARC in human adipose tissue is inﬂuenced by glucose
metabolism and adipokines.
RESEARCH DESIGN AND METHODS—Serum and adipose
tissue biopsies were obtained from morbidly obese nondiabetic
subjects undergoing bariatric surgery and lean control subjects
for analysis of metabolic markers, SPARC, and various cytokines
(RT-PCR). Additionally, 24 obese subjects underwent a very-low-
calorie diet of 1,883 kJ (450 kcal)/day for 16 weeks and serial
subcutaneous-abdominal-adipose tissue (SCAT) biopsies (weight
loss: 28  3.7 kg). Another six lean subjects underwent fast-food–
based hyperalimentation for 4 weeks (weight gain: 7.2  1.6 kg).
Finally, visceral adipose tissue explants were cultured with
recombinant leptin, insulin, and glucose, and SPARC mRNA and
protein expression determined by Western blot analyses.
RESULTS—SPARC expression in human adipose tissue corre-
lated with fat mass and was higher in SCAT. Weight loss induced
by very-low-calorie diet lowered SPARC expression by 33% and
increased by 30% in adipose tissue of subjects gaining weight
after a fast-food diet. SPARC expression was correlated with
leptin independent of fat mass and correlated with homeostasis
model assessment–insulin resistance. In vitro experiments
showed that leptin and insulin potently increased SPARC pro-
duction dose dependently in visceral adipose tissue explants,
while glucose decreased SPARC protein.
CONCLUSIONS—Our data suggest that SPARC expression is
predominant in subcutaneous fat and its expression and secre-
tion in adipose tissue are inﬂuenced by fat mass, leptin, insulin,
and glucose. The proﬁbrotic effects of SPARC may contribute to
metabolic dysregulation in obesity. Diabetes 58:1780–1788,
2009
S
ecreted Protein, Acidic and Rich in Cysteine
(SPARC), a 34-kDa matricellular glycoprotein, is
also known as osteonectin and BM-40. It was
initially found to be secreted from bone (1), but
SPARC is expressed in most tissues and was the ﬁrst
extracellular matrix protein described in adipose tissue
(2,3).
SPARC is a multifunctional protein: it is involved in
osteogenesis, angiogenesis, wound healing, tumorigenesis,
and the pathogenesis of ﬁbrosis involving the kidney (4,5)
and liver (6). SPARC also contributes to collagen ﬁbril
formation in the dermis, and SPARC knockout mice have
reduced collagen content in the dermis (7). More recent
evidence suggests that ﬁbrosis in adipose tissue impairs
metabolic function and reduces the capacity of fat expan-
sion (3). SPARC is secreted from human adipose tissue
and is predominantly derived from adipocytes, where it
has a role in adipocyte differentiation, adipogenesis, and
adipose tissue hyperplasia (2,8); however, it is unknown
whether SPARC contributes to the pathogenesis of insulin
resistance or the metabolic syndrome. The aim of this
study was therefore to study 1) the depot-speciﬁc expres-
sion of SPARC, 2) the association of SPARC with markers
of insulin resistance, 3) the association of SPARC adipose
tissue expression with the adipokines leptin and adiponec-
tin, and 4) the effect of weight loss and weight gain on
adipose tissue SPARC expression.
We determined the adipose tissue depot expression in
visceral fat (VAT) and subcutaneous abdominal adipose
tissue (SCAT) in lean and morbidly obese subjects in
association with adipokine levels and markers of insulin
resistance and explored the gene expression of SPARC in
a longitudinal intervention study involving obese subjects
treated with a very-low-calorie diet (VLCD) to induce
weight loss. Cell culture studies conﬁrmed the regulation
of SPARC by insulin, glucose, and leptin.
RESEARCH DESIGN AND METHODS
Subjects for adipose tissue depot study. Volunteers were recruited from
adults undergoing bariatric surgery (obese group) and routine abdominal
surgery (lean group) at the University Hospital Aintree, Liverpool, after ethical
permission from the local research ethics committee. Subjects with diabetes,
inﬂammatory disorders, or infectious or malignant diseases and subjects on
drug treatments that would likely affect body weight or any study variables,
including endocrine diseases and treatments with systemic glucocorticoids,
were excluded. Lean and obese participants were of similar age and had the
following patient characteristics: obese group—13 men and 26 women, age
44.5  1.4 years (mean  SD), BMI 46.8  1.9 kg/m
2, n  39; lean group—10
men and 8 women, age 42.3  4.1 years, BMI 23.6  0.8 kg/m
2, n  18.
Volunteers attended the clinical investigation unit after an overnight fast from
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1780 DIABETES, VOL. 58, AUGUST 2009midnight for a physical examination and venesection before admission for
surgery. Blood pressure, weight, and height were recorded by the same
observer, and BMI was calculated. Waist circumferences were recorded by
measurement at the midpoint between iliac crest and lowest point of the
costal margin. Body composition was estimated by electrical bio-impedance
measurement using a four-pole system (Bodystat, Isle of Man). Patient
characteristics are shown in Table 1.
VLCD study. Subjects for the VLCD study that aims to identify gene
expression changes in adipose tissue of obese subjects undergoing weight loss
from caloric restriction were recruited after approval by the ethics review
board at University of Gothenburg, Go ¨teborg Sweden. As previously described
(9), a total of 40 obese (BMI 30) men and women age 25–61 years
participated in the study. Smokers and those with pharmacological treatment
of diabetes or lipid-lowering medication were excluded. Of the 40 subjects
recruited, 21 met the criteria for metabolic syndrome based on the modiﬁed
World Health Organization criteria (10): type 2 diabetes or impaired glucose
tolerance as measured by oral glucose tolerance test, lipid disturbance
[triglycerides 1.7 mmol/l or HDL 0.9 mmol/l in men and HDL 1.0 mmol/l
in women], and hypertension (blood pressure 140/90 mmHg). All subjects
were treated with three VLCD meals daily from Cambridge Manufacturing
(Northants, U.K.); the daily energy intake was 1,883 kJ (450 kcal) for 16 weeks
followed by a 2-week period when regular food was gradually reintroduced.
Study assessments were performed at the start of VLCD treatment (week 0),
twice during the VLCD phase (weeks 8 and 16), and 2 weeks after the end of
VLCD treatment (week 18). Anthropometrical measurements, blood pressure
recording, blood sampling, oral glucose tolerance test, and a SCAT biopsy
were performed at each of the four time points. Computed tomography
performed at weeks 0 and 16 was used for adipose tissue area calculations.
SCAT biopsy samples were obtained with a syringe with manually applied
vacuum under local anesthesia and immediately frozen in liquid nitrogen and
stored at 80°C until analysis. Microarray analysis of SCAT biopsies was
performed on 24 patients of which 12 subjects (three women and nine men)
were obese but healthy and 12 subjects (three women and nine men) were
dysmetabolic according to the above criteria. Patient characteristics are
shown in Table 2. Biochemical and anthropometrical measurements and
examinations were performed as described (9). Computed tomography was
used to determine body composition as previously described (11).
Hyperalimenation study. The fast-food study included a total of 18 lean
subjects who accepted a fast-food diet–induced increase in body weight of
5–15% during a period of 4 weeks as described previously (12). The goal for
each individual was to double his or her calorie intake by a diet rich in protein
and saturated animal fat combined with a sedentary lifestyle. The participants
were free from current diseases as judged by medical checkup and history.
Subcutaneous abdominal fat biopsies from six of the subjects were collected
at baseline and after 4 weeks (four men, two women; age 24.1  3 years; BMI
21.4  2.5 kg/m
2) for microarray analysis. Adipocytes were isolated from the
adipose tissue samples by collagenase digestion (collagenase type 1, Worth-
ington, NJ) as described previously (13). Total RNA was extracted using
TRIzol (Invitrogen, Carlsbad, CA) and then further puriﬁed with RNeasy mini
columns (Qiagen, Hilden, Germany). High-quality RNA was conﬁrmed using
an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). Labeled
cRNA from reverse transcription of total RNA was fragmented and hybridized
to HG-U133 Plus 2.0 arrays according to manufacturers’ instructions (Af-
fymetrix, Santa Clara, CA). Fat mass was assessed by dual-energy X-ray
absorptiometry at baseline and after 4 weeks. Patient characteristics are
shown in Table 3.
Characteristics of fat sample donors for in vitro studies. VAT biopsies
were obtained (0800–1000 h) from six women undergoing elective abdominal
surgery [age (mean  SD): 27.5  7 years, BMI: 23.8  2.8 kg/m
2] for adipose
tissue explant studies. Exclusion criteria included known cardiovascular
disease, thyroid disease, neoplasms, current smoking, diabetes, hypertension
(blood pressure 140/90 mmHg), and renal impairment (serum creatinine
120 mol/l). None of the subjects were on any medications for at least 6
months before the study. The local research ethics committee approved the
study, and all patients involved gave their informed consent, in accordance
with the guidelines in the Declaration of Helsinki 2000.
Serum analysis. The subjects recruited at Aintree Hospital for the adipose
tissue depot study had blood taken for analysis of adipokines, glucose
(glucose oxidase method, Yellow Springs), insulin (insulin ELISA, BioSource
Europe S.A.; sensitivity 0.15 IU/ml, intra-assay coefﬁcients of variation
2.5–5.3%; human speciﬁc and with 0% crossreactivity with proinsulin), and
high-sensitivity C-reactive protein (hsCRP, ELISA ImmunDiagnostik AG,
Bensheim, Germany; sensitivity, 0.124 ng/ml, intra-assay coefﬁcients of varia-
tion 5.0–6.0%). The computer-solved homeostasis model assessment method
(14) was used to determine insulin sensitivity and -cell function. Serum levels
TABLE 1
Subject characteristics from Aintree study population
Lean Obese
Signiﬁcance
P value
Sex (male/female) 10/8 13/26 NS
Age (years) 42.3  17.3 44.6  9N S
BMI (kg/m
2) 23.6  2.1 46.9  11.7 0.001
Waist (cm) 88.6  12 130  28 0.001
Systolic blood pressure
(mmHg) 129  13 143  19 0.01
Diastolic blood pressure
(mmHg) 76  98 8  14 0.01
HOMA-IR 1.8  0.3 4.3  0.6 0.001
C-reactive protein
(ng/ml) 1.55  1 11.9  5.7 0.001
Characteristics of lean and obese subjects recruited for biopsies of
SCAT and VAT. Subjects differ in metabolic variables including blood
pressure and HOMA-IR. n  56.
TABLE 2
VLCD study patient characteristics
Baseline 8 weeks 16 weeks 18 weeks
Weight (kg) 119  20 101  17 91  16 91  16***
BMI (kg/m
2) 37.6  4.9 31.8  4.1 28.6  4.1 28.9  3.9***
Waist (cm) 123  12 110  12 101  13 101  13***
Waist-to-hip ratio 1.0  0.08 0.99  0.08 0.95  0.08 0.95  0.08***
Fasting glucose (mmol/l) 6.0  1.6 4.5  0.7 4.5  0.7 5.0  1.0***
OGTT 2-h glucose (mmol/l) 8.2  3.8 7.0  1.9 7.0  2.6 5.9  2.3**
Fasting insulin (mU/l) 16  7.4 7.0  4.1 4.3  2.2 6.3  3.7***
HOMA-IR 4.4  2.7 1.4  0.9 0.9  0.5 1.5  1.3***
Total abdominal fat area (cm
2) 778  191 — 416  171** —
SCAT area (cm
2) 526  166 — 308  135** —
VAT area (cm
2) 241  76 — 101  48** —
Systolic blood pressure (mmHg) 138  17 121  12 117  14 124  16***
Total cholesterol 5.7  1.1 3.9  0.9 4.4  0.8 4.9  0.8***
Serum leptin 38.4  19 9.8  7.5 6.3  5.9 8.8  6.7***
Serum adiponectin 9.0  5.3 11.5  7.3 13.6  6.4 15.2  7.9***
C-reactive protein (mg/l) 5.3  5.8 4.6  5.4 2.4  1.5 2.4  2.2*
SPARC (signal units) 1,857  66 1,186  82*** 1,087  80*** 1,217  82***
Data are means  SD. A computed tomography was performed at weeks 0 and 16 for adipose tissue area calculations. *P  0.05, **P  0.01,
***P  0.001 when compared with baseline week 0 with week 16. n  24. OGTT, oral glucose tolerance test.
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Abingdon, Oxon, U.K.) that has a sensitivity of 0.25 ng/ml and intra-assay
coefﬁcients of variation of 2.5–4.7%. Serum leptin was measured by ELISA
from DRG Diagnostics (Marburg, Germany); sensitivity 1.0 ng/ml, intra-assay
coefﬁcients of variation 3.5–5.0%. All ELISA-based measurements were per-
formed according to manufacturers’ instructions.
Adipose tissue processing: fat depot study. Adipose tissue was obtained
during surgery from subcutaneous and visceral compartments from each
patient (paired samples). Tissue was collected immediately and frozen at
70° for further analysis. Total RNA was isolated from frozen adipose tissue
samples with the RNeasy lipid tissue kit (Qiagen, Crawley, U.K.). The isolated
total RNA was quantiﬁed by measurement of absorbency at 260 and 280 nm,
and its integrity was veriﬁed using agarose gels (1%) stained with ethidium
bromide. Reverse transcription to ﬁrst-strand cDNA was carried out using the
ImProm-II Reverse Transcription System (Promega, Madison, WI), according
to the manufacturer’s instructions. Real-time quantiﬁcation of adipokines and
SPARC mRNA was performed using QuantiTect Multiplex PCR kits (Qiagen),
with commercially available prevalidated and assay-on demand primers and
Quantiprobes, on a ROTORGENE 2000 analyzer (Corbett Research, Cam-
bridge, U.K.) and compared with the housekeeping gene -actin. SPARC
primers were forward 5ATTAGGCTGTTGGTTCAAA 3 and reverse 5 AGCC
CTGGTTCTCCAAAA 3. The use of a duplex conﬁguration allowed simulta-
neous ampliﬁcation of the adipokine gene of interest with the -actin
housekeeping gene. In brief, 1 l cDNA (50 g) was added to a mixture of 2	
QuantiTec Multiplex PCR Master Mix, 20	 Primer Mix for target gene, 20	
Quantiprobe for target gene, 10	 Assay mix for -actin gene, and RNAase-free
water to a ﬁnal volume of 25 l, in different 100-l PCR tubes and in
duplicates. Thermocycling conditions were: 15 min initial activation step
followed by 50 cycles of 45 s of denaturation at 94°C, 45 s of annealing at 56°C,
and 45 s of extension at 76°C. Data were obtained as threshold cycle
(computed tomography) values, which is deﬁned as the fractional cycle
number at which the ﬂuorescence reached 10 times the standard deviation of
the baseline. The increase in ﬂuorescence was measured in real time and
analyzed using the Rotorgene Application Software v6.0 (Build 38). The
relative gene expression of adipokines was calculated according to the
method of Pfafﬂ as a relation to -actin that takes into account the differing
ampliﬁcation efﬁciencies of each gene during the PCR (15).
RNA preparation and DNA microarray analysis (VLCD study). Total
RNA from human tissues was prepared with Qiagen Lipid tissue kit (Qiagen).
Total RNA from adipocytes was prepared with the phenol-chloroform extrac-
tion method of Chomczynski and Sacchi (16). After further puriﬁcation with
RNeasy (Qiagen), the RNA concentration was measured spectrophotometri-
cally. The A260/A280 ratio was 1.8–2.0 and the quality of the RNA was veriﬁed
by agarose gel electrophoresis before reverse transcription into cDNA.
Preparation of cRNA and hybridization in the different studies was performed
according to standard Affymetrix protocols as previously described (9).
Gene expression was measured using the Human Genome U133A DNA
microarray (Affymetrix), composed of 22,283 probe sets representing almost
14,000 expressed genes. Arrays were scanned with a confocal laser scanner
(GeneArray scanner G2500A Hewlett Packard, Palo Alto, CA). The Affymetrix
probesets 200665_at and for control 212667_at were used for SPARC analyses,
and the data from probeset 200665_at were reported.
Tissue distribution analysis. SPARC gene expression in different human
tissues was assessed using DNA microarrays. Duplicate GeneChip HG U133A
expression proﬁles from 17 different tissues were downloaded from the
SymAtlas dataset (http://symatlas.gnf. org/SymAtlas/), as previously described
(17). In addition, our own expression proﬁles, originating from small and large
adipocytes, were included and normalized, as previously described (17).
Primary explant culture. Surgical adipose tissue samples were placed into
sterile containers containing Medium 19 (Sigma Aldrich, Gillingham, U.K.) for
primary adipose tissue culture following a protocol that was a modiﬁcation of
the method described by Fried and Moustaid-Moussa (18). Brieﬂy, 1–3 g of
adipose tissue was minced into 5–10 mg (
1m m
3) fragments, washed with a
230 m mesh (Filter no. 60; Sigma Aldrich, Gillingham, U.K.) and rinsed with
sterile PBS warmed to 37°C. Samples were then transferred to six-well plates
(
50 mg/well) containing 3 ml of Media 199 (Invitrogen, Paisley, U.K.)
supplemented with 50 g/ml gentamicin and 1% FCS (containing insulin at a
concentration of 10
14 M) and cultured for 24 h with or without the addition
of insulin or D-glucose in a 37°C incubator under an atmosphere of 5%
CO2/95% air.
Western blotting. Protein lysates were prepared by homogenizing adipose
tissue in radioimmunoprecipitation lysis buffer (Upstate, Lake Placid, NY)
according to manufacturer’s instructions. Protein samples (40 g/lane) con-
taining SDS sample buffer (5 mol/l urea, 0.17 mol/l SDS, 0.4 mol/l dithiothre-
itol, and 50 mmol/l Tris-HCl, pH 8.0) were subjected to SDS-PAGE (10%
resolving gel) and transferred to polyvinylidene diﬂuoride (PVDF) mem-
branes. The PVDF membranes were incubated with primary rabbit–anti-
human antibody for SPARC (Abcam, Cambridge, U.K.) [1:500 dilution] or
primary rabbit–anti-human antibody for -actin (Cell Signaling Technology,
Beverly, MA) [1:1,000 dilution] overnight at 4°C. The membranes were washed
thoroughly for 60 min with TBS-0.1% Tween before incubation with the
secondary anti-rabbit horseradish peroxidase–conjugated Ig (Dako, Ely, U.K.)
[1:2,000] for1ha troom temperature. Antibody complexes were visualized
using chemiluminescence (ECL; GE Healthcare, Little Chalfont, U.K.). Band
densities were measured using a scanning densitometer coupled to scanning
software Scion Image (Scion Corporation, Frederick, MD), and the mem-
branes were reprobed with the -actin antibody (Cell Signaling Technology;
1:10,000 dilution) to determine equal protein loading.
Statistical methods. Data were analyzed using the package SPSS version 15
(SPSS, Chicago, IL). Positively skewed data were log transformed where
possible, and then analyzed parametrically, or else nonparametric methods
were used. Student’s paired t test and Pearson or Spearman correlation
coefﬁcients were used as appropriate, and multiple regression analysis was
used for correction for dependent variables. For the cell culture comparison,
we used group comparison by Friedman’s ANOVA and post hoc Dunn’s test.
Statistical signiﬁcance was regarded as P  0.05 (two tailed).
RESULTS
SPARC expression in adipose tissue and its depots.
Our data showed that SPARC was expressed in various
human tissues but especially in adipocytes where the
expression was higher in larger cells (Fig. 1A). The
expression in adipocytes was greater than the expres-
sion in stroma cells of adipose tissue (data not shown).
When comparing adipose tissue depot expression,
SPARC expression was higher in SCAT than VAT
(0.81  0.06 vs. 0.50  0.03 signal units, P  0.001, n 
47, Fig. 1B) similar to the expression of the adipokine
leptin in SCAT (1.53  0.1 vs. 0.6  0.03 signal units, P 
0.001, n  47, Fig. 1A).
SPARC and indicators of obesity and obesity-related
inﬂammation. We did not ﬁnd a sex difference in expres-
sion of BMI-matched men and women. Both SCAT- and
VAT-derived SPARC showed a positive correlation with fat
mass (Fig. 2) and with waist circumference (Table 4) in the
depot study. SPARC was strongly correlated with high-
sensitivity C-reactive protein but not with circulating
tumor necrosis factor- (TNF-) or interleukin-6 (IL-6).
SPARC was correlated with local adipose tissue expression
TABLE 3
Hyperalimentation study
Baseline Week 4
Signiﬁcance
P value
Sex (male/female) 4/2 — —
Age (years) 24  3— —
Weight (kg) 64.2  9.3 71.5  13.0 0.01
BMI (kg/m
2) 21.4  2.5 23.7  3.3 0.01
Fat mass (kg) 11.6  6.6 15.8  5.3 0.01
Systolic blood
pressure (mmHg) 115  8 125  14 NS
Fasting glucose
(mmol/l) 5.15  0.72 5.80  0.77 NS
Fasting Insulin (mU/l) 4.2  2.7 8.8  2.9 0.05
HOMA-IR 0.7  0.5 1.63  0.50 0.05
C-reactive protein
(ng/ml) 0.28 0.61 NS
Serum leptin (ng/ml) 6.4  10.9 14.8  17.7 0.05
SPARC (signal units) 3.5  0.8 6.2  0.4 0.05
Patient characteristics of the participants in the fast-food study, their
metabolic proﬁle, and changes in serum leptin and subcutaneous
abdominal adipose tissue expression of SPARC in signal units;
statistical comparison is performed with use of the paired Student’s
t test. n  6.
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0.3, P  0.05), but only SCAT expression of SPARC
correlated with local IL-6 expression (r  0.3, P 
0.05). TNF-, macrophage inﬂammatory protein-1 (MIP-1),
monocyte chemoattractant protein-1 (MCP-1), or regu-
lated upon activation normal T-cell expressed and se-
creted expression showed no association with SPARC
expression (Table 4).
SPARC and markers of insulin resistance. SPARC was
associated with fasting insulin levels (SCAT: r  0.31, P 
0.04; VAT: r  0.34, P  0.02) and homeostasis model
assessment–insulin resistance (HOMA-IR; SCAT: r  0.32,
P  0.03; VAT: r  0.36, P  0.016). In addition, VAT-
SPARC expression but not SCAT-SPARC was correlated
with fasting glucose (r  0.29, P  0.046, Table 4).
SPARC and the adipokines leptin and adiponectin.
VAT-SPARC correlated with VAT leptin (r  0.55, P 
0.001) and SCAT-SPARC with SCAT leptin (r  0.68, P 
0.001); this remained signiﬁcant after correction for fat
mass, waist-to-hip ratio, and HOMA-IR. VAT-SPARC was
negatively correlated with serum adiponectin (r  0.37,
P  0.01) and SCAT-SPARC but not VAT-SPAC negatively
correlated with SCAT adiponectin (r  0.3, P  0.05; Fig.
2C, Table 4).
SPARC and weight loss. Obese subjects in the VLCD
study lost 18 kg in the ﬁrst 8 weeks and an additional 10 kg
by week 16. There was no further weight loss from week
16 to 18. The average SPARC expression in the adipose
tissue of these subjects decreased by 33% in the ﬁrst 8
weeks (P  0.0001, paired t test). However, despite further
weight loss, there was no change in SPARC expression
between 8 and 16 weeks (P  0.74, paired t test). Between
16 and 18 weeks, during which period the subjects went
from VLCD to regular food while remaining weight stable,
the SPARC expression increased signiﬁcantly (20% rise,
P  0.0001, paired t test) and remained signiﬁcantly
correlated with insulin, glucose, and leptin levels but not
adiponectin levels (data not shown). There was no differ-
ence in SCAT-SPARC expression in the group with the
metabolic syndrome, but there was a tendency to a further
decline of SPARC at week 16 (Fig. 3).
SPARC and weight gain. The fast food study subjects
gained on average of 7.2  1.6 kg with resulting BMI of
23.7  3.3 kg/m
2 and fat mass increment of 4.2  5.8 kg.
This resulted in a signiﬁcant increase in fasting insulin by
52%, and HOMA-IR and serum leptin were more than
doubled. SPARC-expression in SCAT increased with hy-
peralimentation in 4 weeks from 3.5  0.8 to 6.2  0.4
signal units (P  0.05; Table 3), and the increment in
SPARC correlated with the amount of weight gain (r 
0.77, P  0.01).
SPARC regulation by insulin and glucose. Cell culture
studies were performed to determine whether the ob-
served correlations of SPARC with metabolic parameters
are because of direct regulation by glucose, leptin, or
insulin. Increasing doses of glucose (5, 10, 20, and 40
mmol/l) decreased SPARC protein expression (5 mmol/l:
100  8 optical density units; 10 mmol/l: 93  6 optical
density units; 20 mmol/l: 24  6 optical density units; 40
mmol/l: 19  4 optical density units [SPARC/-actin],
respectively, n  6; P  0.01, Fig. 4A). In contrast, culture
of VAT with insulin (0, 0.01, 1, and 100 nmol/l) increased
SPARC expression (C: 100  20 optical density units; 0.01
nmol/l: 105  35 optical density units; 1 nmol/l: 156  27
optical density units; 100 nmol/l: 292  30 optical density
units, n  6; P  0.001; Fig. 4B).
SPARC regulation by leptin. Similar to insulin, leptin
treatment of visceral fat explants showed a dose-
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FIG. 1. A: Expression intensity of SPARC in human tissues adapted from the Symatlas in comparison to human adipose tissue. B: SPARC depot
expression in adipose tissue. C: Leptin expression in adipose tissue. SU, signal units; n  47. ***P < 0.01.
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optical density units; 0.1 nmol/l: 271  30 optical density
units; 10 nmol/l: 465  52 optical density units; P  0.001;
Fig. 4C).
DISCUSSION
Adipose tissue plays a key role in energy homeostasis both
as an energy store and as an endocrine organ. Dysfunction
of adipose tissue fat storage leads to fat deposition in
other organs as ectopic fat and results in disadvantageous
metabolic consequences as most apparent in subjects with
familial lipodystrophy (19). The cause of impaired adipose
tissue storage capacity is unclear and SPARC that inﬂu-
ences matricellular composition could contribute to its
development by inhibition of adipocyte differentiation.
Disturbance of the 3D extracellular matrix (ECM), for
example, increased rigidity by increased collagen 1 con-
tent and has previously been shown to compromise in
vitro adipocyte differentiation (20), and collagen dysregu-
lation has recently been attributed to metabolic dysregu-
lation (3).
The following attributes make SPARC a likely candidate
to limit fat deposition in adipose tissue itself. Although it is
an evolutionarily conserved collagen-binding glycoprotein,
it does not contribute to the structure of the ECM, but it
was recently shown to be a ligand of the integrin receptor
5-1–integrin (21) and inhibit adipogenesis through stim-
ulation of -catenin signaling (8), which is part of the Wnt
pathway that enhances osteoblastogenesis alongside the
inhibition of adipogenesis (22). SPARC null mice have a
phenotype marked by an increased subcutaneous fat dep-
osition, reduction in collagen 1 in SPARC-null fat, adipo-
cytes of higher diameters, and fat pads with an increase in
adipocyte number (23).
The results of our study showed an increase of SPARC
expression with increased fat mass that is consistent with
previous reports showing a higher expression of SPARC in
rodent obesity (24) and elevated SPARC levels in obese
subjects (25). In addition, this is the ﬁrst study to highlight
the depot-speciﬁc expression of SPARC in humans.
SPARC/osteonectin is expressed in various human tissues
with particularly high expression in subcutaneous abdom-
inal fat where is appears to be secreted primarily by
adipocytes in comparison to the adipose tissue stromal
fraction that is consistent with previous ﬁndings (2).
Subjects with familial lipodystrophy lack SCAT, and the
metabolic consequences could be attributed to the limita-
tion of subcutaneous tissue expansion to which SPARC as
an inhibitor of adipogenesis (8) with higher expression in
SCAT may contribute.
This is the ﬁrst study to assess metabolic parameters in
combination with adipose tissue SPARC expression. We
found a positive correlation with fasting insulin, fasting
glucose, and HOMA-IR and waist circumference as well as
hsCRP for subcutaneous and visceral depots. However, we
did not ﬁnd a correlation of SPARC with fasting lipids or
blood pressure, which may in part be masked by treatment
A
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FIG. 2. SPARC and relation to fat mass, HOMA-IR, and adipokine expression. A: Depot expression of SPARC and its correlation with fat mass.
B: VAT and SCAT-SPARC expression and HOMA-IR. C: VAT expression of adiponectin and SPARC. D: The correlation of SPARC expression with
leptin. Values are expressed in signal units.
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(not shown).
Higami et al. (26) examined genes downregulated by
energy restriction in epididymal fat in mice, and SPARC
was one of the prominently affected genes lowered by
long-term energy restriction. Consistent with this we
have found a strong downregulation of SPARC with
weight loss after 8 weeks of a VLCD and an increment of
SPARC with weight gain. Although HOMA-IR improved
with weight loss in our VLCD study population, and
SCAT-SPARC expression correlated with fasting insulin
and HOMA-IR, the SPARC expression was no different
in the BMI-matched groups with and without the meta-
bolic syndrome, which is explained and consistent with
the lack of correlation of SPARC with blood pressure
and lipids. Leptin is a strong predictor of SPARC in the
depot study as well as the VLCD study in which it is
independent of the BMI at baseline. SPARC remains
correlated with leptin expression but loses its associa-
tion with weight loss after 8 weeks, after which subjects
continued to lose weight. The strong correlation with
insulin, glucose, and leptin in the depot and the VLCD
study prompted us to study and conﬁrm their regulation
by further in vitro studies, while adiponectin showed an
inverse correlation with SPARC expression in SCAT but
not VAT and thus appeared less likely to be because of
a direct effect.
Culture of visceral explants showed that glucose low-
ered and insulin and leptin increased SPARC expression
that apart from the glucose correlation is consistent with
the ﬁndings in the clinical studies. However, circulating
glucose in vivo showed a positive correlation with
SPARC-AT expression that contradicts the in vitro study in
which supraphysiological glucose levels lower SPARC.
The lack of inﬂuence of circulating glucose levels may be
explained by the insulin resistance of adipocytes for
glucose transport in obese individuals. In diabetic sub-
jects, we would expect the glucose levels required to
lower SPARC to be supraphysiological as found in marked
hyperglycemia that is usually avoided by antidiabetic
treatment. Although we show that SPARC is regulated by
leptin, SPARC in turn suppresses leptin gene expression in
mouse preadipocytes (21), which may explain the high
leptin levels observed in SPARC knockout mice (23).
It was suggested that SPARC may be involved in inﬂam-
matory processes (27,28), but data from our study show
only a correlation of adipose tissue SPARC expression
with the local expression of the MMIF-1—a proinﬂamma-
tory adipocytokine (29). An association of SPARC with
MMIF was to our knowledge only reported in connection
D
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FIG. 2. Continued.
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sion of both (30). Thus, the interaction of SPARC and
MMIF remains to be conﬁrmed but may explain a potential
association of SPARC with diabetes with MMIF being
associated with the pathogenesis of type 1 and type 2
diabetes and latter among others through a decrease in
insulin signal transduction (31).
Much pathology related to diabetes and obesity has
been linked with SPARC. An increased SPARC expression
was found in rodent models of diabetic nephropathy (32),
and SPARC null mice were shown to be protected from
renal ﬁbrosis (27). Increased circulating levels of SPARC
have been observed in subjects with cardiovascular dis-
ease (25). SPARC is also expressed in human retinal
endothelial cells (33), and with its close interaction with
VEGF and PAI-1 (34,35) it may further the progression of
diabetic retinopathy. Furthermore, SPARC is linked with
tumorigenesis and appears to favor certain tumors (36),
although its exact role in tumor development is controver-
sial (37) and it remains to be shown whether SPARC could
contribute to the association of obesity and some cancers
(38).
Apart from focusing on the potential advantages of
lowering SPARC levels, the inducers of SPARC excess
such as hyperleptinemia in subjects with leptin resistance
and hyperinsulinemia in type 2 diabetes require similar
TABLE 4
SPARC and metabolic parameters and cytokines
SCAT VAT
Waist circumference (cm) R  0.37, P < 0.01 R  0.23, P < 0.05
Fat mass (kg) R  0.4, P < 0.01 R  0.3, P < 0.05
Total cholesterol (mmol/l) R  0.008, P  NS R  0.23, P < 0.05
Fasting insulin (IU/ml) R  0.31, P < 0.05 R  0.34, P < 0.05
Fasting glucose (mmol/l) R  0.23, P  NS R  0.3, P < 0.05
HOMA-IR R  0.32, P < 0.05 R  0.36, P < 0.05
Circulating leptin (ng/ml) R  0.38, P < 0.05 R  0.17, P  NS
Circulating adiponectin (ng/ml) R  0.22, P  NS R  0.37, P < 0.05
Circulating IL-6 (ng/ml) R  0.26, P  NS R  0.01, P  NS
Circulating TNF- (ng/ml) R  0.16, P  NS R  0.03, P  NS
hsCRP (mmol/l) R  0.44, P < 0.01 R  0.31, P < 0.05
Adipose tissue leptin R  0.68, P < 0.001 R  0.55, P < 0.001
Adipose tissue adiponectin R  0.3, P < 0.05 R  0.01, P  NS
Adipose tissue IL-6 R  0.3, P < 0.05 R  0.014, P  NS
Adipose tissue MMIF R  0.3, P < 0.05 R  0.3, P < 0.05
Adipose tissue TNF- R  0.07, P  NS R  0.03, P  NS
Adipose tissue MIP-1 R  0.03, P  NS R  0.47, P  NS
Adipose tissue MCP-1 R  0.055, P  NS R  0.14, P  NS
Adipose tissue RANTES R  0.077, P  NS R  0.017, P  NS
SPARC depot-speciﬁc expression in relation to metabolic parameters, circulating cytokine levels, and adipose tissue expression of
adipokine/cytokine corresponding to the depot studied. RANTES, regulated upon activation normal T-cell expressed and secreted. n  56,
signiﬁcant correlations are shown in bold.
VLCD R
S
P
A
R
C
 
e
x
p
r
e
s
s
i
o
n
 
i
n
 
O
D
*** *** ***
***
**
P=NS
0
500
1,000
1,500
2,000
2,500
W0 W8 W16 W18
METS+
METS -
FIG. 3. SPARC during VLCD 16-week 450 kcal/day in subjects with (METS) and without (METS) the metabolic syndrome. Data from SPARC
adipose tissue expression of subjects of both groups were compared with their baseline levels (top) and the within-patient variation with the
previous time point. R, refeeding; W, week. **P < 0.01, ***P < 0.001, n  24.
SPARC’S METABOLIC REGULATION IN HUMAN ADIPOSE TISSUE
1786 DIABETES, VOL. 58, AUGUST 2009attention. Leptin is a proinﬂammatory molecule, and it has
been suggested that leptin is permissive in the pathogen-
esis of liver ﬁbrosis as shown by protection of leptin-
deﬁcient mice from ﬁbrosis during steatohepatitis or in
response to chronic toxic liver injury (39). As such,
hyperleptinemia in adipose tissue may through upregula-
tion of SPARC also induce adipose tissue ﬁbrosis that
requires further study.
In summary, our study showed that SPARC-AT expres-
sion is related to human metabolism and SPARC expres-
sion that is predominant in SCAT is upregulated by insulin
and leptin. Together with the previous reported conse-
quences of SPARC in other tissues, a role for SPARC in the
development of obesity- and diabetes-related complica-
tions is likely. Further research is required to show
whether increased adipose tissue SPARC limits the expan-
sion of normal adipose tissue in response to energy excess
and promotes ectopic fat deposition and associated met-
abolic dysfunction.
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